Alex Tong CPA & Associates since Jan 2004
President
Celion Networks Jan 2001 - Jan 2002
Director of Engineering
Fujitsu Network Communications Jan 2000 - Jan 2001
System Engineer
Fujitsu 1999 - 2001
System Engineer
TRW Jan 1989 - Jan 1997
Aerospace Engineer
Education:
The University of Texas at Arlington 1974 - 1983
BS, BBA, Acccounting, Electrical Engineering
Oncocept Consultants
Executive Director
Novarx Corporation Jul 2011 - Jan 2013
Director of Immunology
Gradalis, Inc. Jan 2008 - May 2011
Director of Immunology and Grants Development
American Amateur Karate Federation Jan 2008 - May 2011
President
Mary Crowley Cancer Research Centers Jan 2004 - Dec 2007
Director of Preclinical Operations
Education:
Oregon Health & Science University
Doctorates, Doctor of Philosophy
Oregon Health and Science University School of Medicine
Doctorates, Doctor of Philosophy, Microbiology, Immunology
University of Oregon
Bachelors, Bachelor of Arts, Biology
Skills:
Immunology Cancer Cell Clinical Development Clinical Trials Assay Development Biotechnology Translational Research Clinical Research Vaccines Cell Culture Molecular Biology Elisa Science In Vitro Life Sciences Cell Biology Gcp Biomarkers Laboratory R&D Oncology Fda Neuroscience Toxicology Drug Discovery Gene Therapy In Vivo Teaching Biochemistry Glp Ind Lifesciences Microbiology Infectious Diseases Antibodies Pcr Molecular Cloning Western Blotting Pharmacology Microscopy Flow Cytometry Cell Based Assays Virology Therapists Biomarker Discovery Genetics Validation Clinical Therapeutics
The UPS Store, Inc San Diego, CA Nov 2009 to Jan 2015 Lead Database AnalystTrust Company of the West Los Angeles, CA Nov 2006 to Nov 2009 Database AdministratorUCLA Student Loan Services and Collections Los Angeles, CA Oct 2004 to Nov 2006 Programmer Analyst
Education:
Texas Tech University Tech, Texas, US Jan 1997 to May 2000 B.S. in Computer Science
Skills:
SQL, Microsoft SQL Server, Administration, Development, SSRS, SSIS
Alex W. Tong - Dallas TX, US Yu Yang - Allen TX, US Donald Rao - Dallas TX, US Phillip B. Maples - Pilot Point TX, US Neil Senzer - Dallas TX, US John J. Nemunaitis - Cedar Hill TX, US Zhaohui Wang - Grapevine TX, US
Compositions and methods of augmenting the anti-tumor activities of docetaxel and other taxanes by combination with a bi-functional small hairpin RNA (bi-shRNA) is described herein. The instant invention describes the interactive outcome of STMN1 knockdown with docetaxel. In vitro docetaxel (DOC) dose response assessments with or without co-treatment with bi-shRNAin CCL-247 and SK-MEL-28 melanoma cells indicated that STMN1 knockdown significantly reduced DOC concentration needed to inhibit cancer cell growth by 50% (IC) of CCL-247 cells from 1.80.2 to 0.60.4 nm (n=3, p
Anti-Tumor Activity Of An Oncolytic Adenovirus-Delivered Oncogene Sirna
Alex W. Tong - Dallas TX, US Yu An Zhang - Plano TX, US John J. Nemunaitis - Dallas TX, US Yuqiao Shen - Orinda CA, US Po-hsun Chen - Addison TX, US Shirley K. Samuel - Irving TX, US
Assignee:
BAYLOR RESEARCH INSTITUTE - Dallas TX MUREX PHARMACEUTICALS - Dallas TX BAYLOR UNIVERSITY - Waco TX
International Classification:
A61K 48/00 C12N 15/861
US Classification:
424 932, 435456
Abstract:
The present invention includes compositions and methods for the knockdown of one or more genes to a target cell in need of gene therapy by using an siRNA transgene that is integrated into a replication-competent, oncolytic adenovirus.